Evidence map›Paper›PMID 34320903›Full record

ArticleSmall GTPases2022

Targeting Rac1 for the prevention of atherosclerosis among U.S. Veterans with inflammatory bowel disease.

S Scott Sutton, Joseph Magagnoli, Tammy H Cummings, James W Hardin

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Small GTPases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

S Scott SuttonDorn Research Institute, Columbia VA Health Care System, Columbia, SC, USA.ORCID 0000-0002-3889-6178
Joseph MagagnoliDorn Research Institute, Columbia VA Health Care System, Columbia, SC, USA.ORCID 0000-0002-8568-0097
Tammy H CummingsDorn Research Institute, Columbia VA Health Care System, Columbia, SC, USA.
James W HardinDorn Research Institute, Columbia VA Health Care System, Columbia, SC, USA.
University of South Carolina · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Evidence suggests that Ras-related C3 botulinum toxin substrate 1 (Rac1) might be a target in atherosclerotic disease (AD). We hypothesize that due to their ability to inhibit Rac1, thiopurines are associated with a lower risk of AD. We fit a time-dependent cox proportional hazards model estimating the hazard of AD among a national cohort of US veterans with inflammatory bowel disease. Patients exposed to thiopurines had a 7.5% lower risk of AD (HR = 0.925; 95% CI = (0.87-0.984)) compared to controls. The propensity score weighted analysis reveals thiopurine exposure reduces the risk of AD by 6.6% (HR = 0.934; 95% CI = (0.896-0.975)), compared to controls. Further exploration and evaluation of Rac1 inhibition as a target for AD is warranted.

Indexed as

AtherosclerosisInflammatory Bowel DiseasesVeteransCohort StudiesHumansImmunosuppressive Agentsrac1 GTP-Binding ProteinImmunosuppressive Agentsrac1 GTP-Binding ProteinRAC1 protein, humanatherosclerosiscohortinflammatory bowel diseaseRac1thiopurines

Identifiers

PMID34320903
PMCPMC9707539
OpenAlexW3184542788

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.